Exploring the mechanism of sunflower seed oil against Alzheimer’s disease through experimental and network pharmacology studies DOI

Yashodhan Desai,

Deepak Karunakaran,

Juhi Singh

et al.

Indian Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 56(6), P. 396 - 404

Published: Nov. 1, 2024

Abstract: OBJECTIVES: With the prevalence of Alzheimer’s disease (AD) increasing exponentially, there has been a shift in focus drug discovery for AD from treating symptoms to preventing development disease. Several natural compounds are extensively studied as neuroprotectives progression. Helianthus annuus seed oil (HA) is widely used cooking and abundant antioxidant activity. Therefore, we evaluated effect HA mice model scopolamine-induced amnesia explored potential underlying mechanisms. METHODS: Twenty-four male were administered orally with either distilled water (control scopolamine groups) or treatment groups (HA 100 200 mg/kg) 8 consecutive days. All groups, except control group, received an intraperitoneal injection at dose 1 mg/kg. Subsequently, novel object recognition task cognition assessment open field tests locomotory activity performed. In addition, network analysis was performed identify key bioactives targets against AD. Further, binding affinity verified by molecular docking analysis. RESULTS: (100 mg/kg significantly ameliorated memory compared suggesting protective cognitive impairment. Network indicated that HA, chlorogenic acid, oleic acid act through multiple pathways, particularly mitogen-activated protein kinase (MAPK) pathway, ameliorate symptoms. Importantly, showed good MAPKs, TP53, EP300. CONCLUSION: therapeutic benefits acting MAPK pathway. However, further studies need be done confirm results derived translate use dietary supplement

Language: Английский

Metformin Improves Spatial Memory and Reduces Seizure Severity in a Rat Model of Epilepsy and Alzheimer’s Disease comorbidity via PI3K/Akt Signaling Pathway DOI

Suélen Santos Alves,

Letícia Rossi,

José Antônio Cortes de Oliveira

et al.

Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown

Published: March 24, 2025

Language: Английский

Citations

0
Evolution of Alzheimer’s Disease Therapeutics: From Conventional Drugs to Medicinal Plants, Immunotherapy, Microbiotherapy and Nanotherapy DOI Creative Commons
Emma Ortiz, Pedro Montes, Citlali Ekaterina Rodríguez-Pérez

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(1), P. 128 - 128

Published: Jan. 17, 2025

Alzheimer's disease (AD) represents an escalating global health crisis, constituting the leading cause of dementia among elderly and profoundly impairing their quality life. Current FDA-approved drugs, such as rivastigmine, donepezil, galantamine, memantine, offer only modest symptomatic relief are frequently associated with significant adverse effects. Faced this challenge in line advances understanding pathophysiology neurodegenerative condition, various innovative therapeutic strategies have been explored. Here, we review novel approaches inspired by advanced knowledge underlying pathophysiological mechanisms disease. Among alternatives, immunotherapy stands out, employing monoclonal antibodies to specifically target eliminate toxic proteins implicated AD. Additionally, use medicinal plants is examined, synergistic effects components may confer neuroprotective properties. The modulation gut microbiota also addressed a peripheral strategy that could influence neuroinflammatory degenerative processes brain. Furthermore, potential emerging approaches, microRNAs regulate key cellular nanotherapy, which enables precise drug delivery central nervous system, analyzed. Despite promising these strategies, incidence continues rise. Therefore, it proposed achieving effective treatment future require integration combined maximizing different interventions.

Language: Английский

Citations

0
Diverse Applications of the Anti-Diabetic Drug Metformin in Treating Human Disease DOI Creative Commons
Chris-Tiann Roberts,

Nils Raabe,

Lara Wiegand

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1601 - 1601

Published: Nov. 27, 2024

Metformin is a commonly used drug for treating type 2 diabetes. an inexpensive with low/no side effects and well tolerated in human patients of different ages. Recent therapeutic strategies disease have considered the benefits repurposing. This includes use anti-diabetic metformin. Accordingly, anti-inflammatory, anti-cancer, anti-viral, neuroprotective, cardioprotective potentials metformin deemed it suitable candidate plethora diseases. As results from preclinical studies using cellular animal model systems appear promising, clinical trials context non-diabetes-related illnesses been started. Here, we aim to provide comprehensive overview potential models its suggested relationship epigenetics ailments epigenetic components.

Language: Английский

Citations

1
Exploring the mechanism of sunflower seed oil against Alzheimer’s disease through experimental and network pharmacology studies DOI

Yashodhan Desai,

Deepak Karunakaran,

Juhi Singh

et al.

Indian Journal of Pharmacology, Journal Year: 2024, Volume and Issue: 56(6), P. 396 - 404

Published: Nov. 1, 2024

Abstract: OBJECTIVES: With the prevalence of Alzheimer’s disease (AD) increasing exponentially, there has been a shift in focus drug discovery for AD from treating symptoms to preventing development disease. Several natural compounds are extensively studied as neuroprotectives progression. Helianthus annuus seed oil (HA) is widely used cooking and abundant antioxidant activity. Therefore, we evaluated effect HA mice model scopolamine-induced amnesia explored potential underlying mechanisms. METHODS: Twenty-four male were administered orally with either distilled water (control scopolamine groups) or treatment groups (HA 100 200 mg/kg) 8 consecutive days. All groups, except control group, received an intraperitoneal injection at dose 1 mg/kg. Subsequently, novel object recognition task cognition assessment open field tests locomotory activity performed. In addition, network analysis was performed identify key bioactives targets against AD. Further, binding affinity verified by molecular docking analysis. RESULTS: (100 mg/kg significantly ameliorated memory compared suggesting protective cognitive impairment. Network indicated that HA, chlorogenic acid, oleic acid act through multiple pathways, particularly mitogen-activated protein kinase (MAPK) pathway, ameliorate symptoms. Importantly, showed good MAPKs, TP53, EP300. CONCLUSION: therapeutic benefits acting MAPK pathway. However, further studies need be done confirm results derived translate use dietary supplement

Language: Английский

Citations

0